Table 5.
Overview of allergen derivatives developed for immunotherapy and its features (table adapted from Marth et al. [159]).
| Recombinant Wildtype Allergens [129,160,161,162,163,164] | Derivatives of Recombinant Allergens [116,165,166,167,168,169,170,171,172,173,174,175,176,177,178] | T-cell Peptides [179,180,181,182,183,184,185] | Peptide Carrier Fusion Proteins [186,187,188,189,190,191,192,193] | |
|---|---|---|---|---|
| Immune response: | ||||
| IgE reactive | + | +/− | − | − |
| T-cell reactive | + | + | + | − |
| Induce protective antibodies | + | + | − | + |
| Possible side effects: | ||||
| IgE | + | − | − | − |
| T-cell mediated | + | + | + | − |
+ Induces a response; − does not induce a response; +/− can induce a response/allergen dependent; derivatives of recombinant allergens, including mutants, fragments and oligomers.